Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Evoke Pharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

EXTENDS MARKET EXCLUSIVITY FOR GIMOTI TO NOVEMBER 2038, NEARLY TWO ADDITIONAL YEARS BEYOND ORIGINAL 2036 PROJECTION EXTENDS MARKET EXCLUSIVITY FOR GIMOTI TO NOVEMBER 2038, NEARLY TWO ADDITIONAL YEARS BEYOND ORIGINAL 2036 PROJECTION

EVOKE PHARMA ANNOUNCES ISSUANCE OF NEW U.S. PATENT FOR GIMOTI WITH EXTENDED EXCLUSIVITY TO LATE 2038

SOLANA BEACH, CALIF., JULY 09, 2025 (GLOBE NEWSWIRE) -- EVOKE PHARMA, INC. (NASDAQ: EVOK), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED PRIMARILY ON TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES WITH AN EMPHASIS ON GIMOTI (METOCLOPRAMIDE) NASAL SPRAY, TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTICE OF ALLOWANCE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR A U.S. PATENT APPLICATION COVERING THE USE OF GIMOTI IN PATIENTS WITH MODERATE TO SEVERE SYMPTOMS OF GASTROPARESIS.

EVOKE PHARMA RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION FOR GIMOTI EXTENDING ORANGE BOOK LISTINGS TO 2036

Q1 2025 NET PRODUCT SALES INCREASED 77% YEAR-OVER-YEAR TO $3.1 MILLION SUSTAINED MOMENTUM DRIVEN BY GROWING PRESCRIBER ADOPTION AND REPEAT PATIENT USE SOLANA BEACH, CALIF., MAY 13, 2025 (GLOBE NEWSWIRE) -- EVOKE PHARMA, INC.(NASDAQ: EVOK), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON TREATMENTS FOR GASTROINTESTINAL (GI) DISORDERS WITH AN EMPHASIS ON GIMOTI, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE.

EVOKE PHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SOLANA BEACH, CALIF., APRIL 28, 2025 (GLOBE NEWSWIRE) -- EVOKE PHARMA, INC. (NASDAQ: EVOK), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON TREATMENTS FOR GASTROINTESTINAL (GI) DISORDERS WITH AN EMPHASIS ON GIMOTI, TODAY ANNOUNCED THAT A NEW ABSTRACT COMPARING THE INCIDENCE OF TARDIVE DYSKINESIA (TD) IN PATIENTS RECEIVING CONTINUOUS VERSUS INTERMITTENT ORAL METOCLOPRAMIDE (OMCP) TREATMENT HAS BEEN ACCEPTED FOR PRESENTATION AT DIGESTIVE DISEASE WEEK (DDW) 2025, TAKING PLACE MAY 36, 2025, IN SAN DIEGO, CA.

EVOKE PHARMA TO PRESENT NEW DATA COMPARING TARDIVE DYSKINESIA INCIDENCE IN CONTINUOUS VS INTERMITTENT METOCLOPRAMIDE USE AT DDW 2025

Q4 2024 REVENUE INCREASED 24.6%OVER Q3 2024; FULL-YEAR 2024 REVENUE GREW 97.8% YEAR-OVER-YEAR STRONG GROWTH IN KEY COMMERCIAL METRICS, INCLUDING PRESCRIBER BASE, FILL RATES, AND PATIENT ENROLLMENTS SECURED $14.3 MILLION NET PROCEEDS IN FINANCINGS, ENSURING NASDAQ COMPLIANCE PRESENTED COMPELLING HEALTHCARE RESOURCE UTILIZATION DATA ON GIMOTI AT KEY GASTROENTEROLOGY CONFERENCES, INCLUDING AN AWARD-WINNING STUDY ON GLP-1 USERSWITH DIABETIC GASTROPARESIS AT ACG 2024 CONFERENCE CALL AND WEBCAST TO BE HELD TODAY AT 4:30 P.M. ET SOLANA BEACH, CALIF.

EVOKE PHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SOLANA BEACH, CALIF., MARCH 06, 2025 (GLOBE NEWSWIRE) -- EVOKE PHARMA, INC.(NASDAQ: EVOK), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES WITH AN EMPHASIS ON GIMOTI (METOCLOPRAMIDE) NASAL SPRAY, TODAY ANNOUNCED THAT THE COMPANY IS SCHEDULED TO RELEASE ITS FOURTH QUARTER AND FULL YEAR 2024 ON THURSDAY, MARCH 13, 2025, AFTER THE MARKET CLOSES.

EVOKE PHARMA TO REPORT FOURTH QUARTER AND FULL YEAR 2024 RESULTS ON MARCH 13, 2025

SOLANA BEACH, CALIF., FEB. 24, 2025 (GLOBE NEWSWIRE) -- EVOKE PHARMA, INC. (NASDAQ: EVOK), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED PRIMARILY ON TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES WITH AN EMPHASIS ON GIMOTI (METOCLOPRAMIDE) NASAL SPRAY, TODAY ANNOUNCED THE APPOINTMENT OF GREG PYSZCZYMUKA TO ITS BOARD OF DIRECTORS, EFFECTIVE FEBRUARY 20, 2025. THIS MARKS THE SECOND BOARD MEMBER APPOINTMENT BY NANTAHALA CAPITAL MANAGEMENT, REINFORCING ITS CONTINUED CONFIDENCE IN EVOKE'S COMMERCIAL STRATEGY AND GROWTH POTENTIAL.

EVOKE PHARMA ANNOUNCES THE APPOINTMENT OF GREG PYSZCZYMUKA TO THE BOARD OF DIRECTORS

FDA POSTS UPDATE AS MECHANISM TO OBTAIN UNAPPROVED DOMPERIDONE EXPECTED TO LOSE SUPPLY IN EARLY 2025 GIMOTI REMAINS ONLY APPROVED DRUG SHOWN TO REDUCE HOSPITALIZATIONS, EMERGENCY ROOM AND MEDICAL OFFICE VISITS AND RELATED COSTS COMPARED TO ORAL METOCLOPRAMIDE SOLANA BEACH, CALIF., DEC. 19, 2024 (GLOBE NEWSWIRE) -- EVOKE PHARMA, INC. (NASDAQ: EVOK), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED PRIMARILY ON TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES WITH AN EMPHASIS ON GIMOTI(METOCLOPRAMIDE) NASAL SPRAY, UNDERSCORES ITS COMMITMENT TO PATIENTS AND HEALTHCARE PROVIDERS MANAGING GASTROPARESIS IN LIGHT OF FDA'S RECENT UPDATE REGARDING DOMPERIDONE SUPPLY.

EVOKE PHARMA HIGHLIGHTS GIMOTI AS A LEADING SOLUTION FOR GASTROPARESIS TREATMENT AS DOMPERIDONE SUPPLY ENDS

SOLANA BEACH, CALIF., DEC. 03, 2024 (GLOBE NEWSWIRE) -- EVOKE PHARMA, INC. (NASDAQ: EVOK), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED PRIMARILY ON TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES WITH AN EMPHASIS ON GIMOTI(METOCLOPRAMIDE) NASAL SPRAY, TODAY ANNOUNCED THAT IT HAS RECEIVED NOTICES OF ALLOWANCE FOR TWO U.S. PATENT APPLICATIONS BY THE UNITED STATES PATENT AND TRADEMARK OFFICE, FURTHER EXPANDING THE COMPANY'S ROBUST INTELLECTUAL PROPERTY ESTATE FOR ITS INNOVATIVE GIMOTI (METOCLOPRAMIDE) NASAL SPRAY.

EVOKE PHARMA RECEIVES NOTICES OF ALLOWANCE FOR TWO ADDITIONAL US PATENT APPLICATIONS PROTECTING GIMOTI

GIMOTI THIRD QUARTER NET PRODUCT SALES OF $2.7 MILLION, HIGHEST QUARTERLY REVENUE EVER WITH A 70% INCREASE YEAR-OVER-YEAR

Evoke Pharma, Inc.

EVOK

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Evoke Pharma, Inc.

EVOK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

EVOK